Drug recall · December 25, 2024
Nebivolol Tablets recall
Why: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Nebivolol Tablets, 2.5. mg, 30-count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520. NDC: 59651-137-30
- Lots / codes
Lot #: NB0224001A and NB0224001B, Exp. Date 04/2027
- Company
- Aurobindo Pharma USA Inc, East Windsor, NJ
- Distribution
- Nationwide in the USA
- Initiated
- December 6, 2024 · Voluntary: Firm initiated
- Classified
- December 16, 2024
- Reported
- December 25, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Nebivolol
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.